Literature DB >> 4054193

CNS-related side-effects with metoprolol and atenolol.

J R Cove-Smith, C A Kirk.   

Abstract

Vivid and bizarre dreams, hallucinations, sleep disturbance and psychosis have all been described following treatment with beta-blockers. It has been suggested that these central nervous system (CNS) side-effects are related to the degree of lipophilicity of the beta-blocker. A randomized double-blind crossover study was performed to compare the incidence of CNS side-effects with atenolol and metoprolol in hypertensive patients who had reported CNS side-effects with lipophilic beta-blockers. Eleven women and six men completed the study, in which a 30-item psychiatric questionnaire was used to detect changes in psychological status and possible CNS side-effects. Discontinuation of the original lipophilic beta-blocker produced a significant improvement in quality of sleep, dreams, concentration, memory, energy, and anxiety. No significant CNS side-effects were reported with atenolol, but introduction of metoprolol caused a significant increase in the incidence of sleep disturbance (p less than 0.01) and restless nights (p less than 0.05), as well as failure to achieve satisfactory sexual intercourse (p less than 0.05). When compared with atenolol, metoprolol was associated with a significantly higher incidence of restless disturbed nights (p less than 0.05). Blood pressure control was identical for both beta-blockers. This study appears to confirm the association between CNS-related side-effects and the lipophilicity of beta-blockers.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4054193     DOI: 10.1007/BF00543713

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  7 in total

1.  Propranolol psychosis.

Authors:  H S Fraser; A C Carr
Journal:  Br J Psychiatry       Date:  1976-11       Impact factor: 9.319

2.  Nature and incidence of unwanted effects with atenolol.

Authors:  W T Simpson
Journal:  Postgrad Med J       Date:  1977       Impact factor: 2.401

3.  Defective metabolism of metoprolol in poor hydroxylators of debrisoquine.

Authors:  M S Lennard; J H Silas; S Freestone; J Trevethick
Journal:  Br J Clin Pharmacol       Date:  1982-08       Impact factor: 4.335

4.  Beta-adrenoceptor blockers and the blood-brian barrier.

Authors:  G Neil-Dwyer; J Bartlett; J McAinsh; J M Cruickshank
Journal:  Br J Clin Pharmacol       Date:  1981-06       Impact factor: 4.335

5.  An investigation of the comparative liposolubilities of beta-adrenoceptor blocking agents.

Authors:  P B Woods; M L Robinson
Journal:  J Pharm Pharmacol       Date:  1981-03       Impact factor: 3.765

Review 6.  The clinical importance of cardioselectivity and lipophilicity in beta blockers.

Authors:  J M Cruickshank
Journal:  Am Heart J       Date:  1980-08       Impact factor: 4.749

7.  Visual hallucinations and illusions with propranolol.

Authors:  R Fleminger
Journal:  Br Med J       Date:  1978-05-06
  7 in total
  17 in total

1.  Risk factors for depressive symptoms in glaucoma patients: a nationwide case-control study.

Authors:  Chien-Chia Su; Judy Yi-Chu Chen; Tsing-Hong Wang; Jehn-Yu Huang; Chung-May Yang; I-Jong Wang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-06-07       Impact factor: 3.117

2.  Portable Sleep Monitoring Systems: Broadening the Horizons.

Authors:  Naima Covassin; Virend K Somers
Journal:  J Clin Sleep Med       Date:  2017-06-15       Impact factor: 4.062

3.  Cognitive function in hypertensives treated with atenolol or propranolol.

Authors:  D M Palac; R D Cornish; W J McDonald; D A Middaugh; D Howieson; S P Bagby
Journal:  J Gen Intern Med       Date:  1990 Jul-Aug       Impact factor: 5.128

Review 4.  Metoprolol: a pharmacoeconomic and quality-of-life evaluation of its use in hypertension, post-myocardial infarction and dilated cardiomyopathy.

Authors:  D H Peters; P Benfield
Journal:  Pharmacoeconomics       Date:  1994-10       Impact factor: 4.981

Review 5.  Clinical pharmacokinetics of beta-adrenoceptor antagonists. An update.

Authors:  J G Riddell; D W Harron; R G Shanks
Journal:  Clin Pharmacokinet       Date:  1987-05       Impact factor: 6.447

Review 6.  Adverse reactions and interactions with beta-adrenoceptor blocking drugs.

Authors:  R V Lewis; D G McDevitt
Journal:  Med Toxicol       Date:  1986 Sep-Oct

Review 7.  CNS-related (side-)effects of beta-blockers with special reference to mechanisms of action.

Authors:  W P Koella
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

8.  In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors.

Authors:  A Saheki; T Terasaki; I Tamai; A Tsuji
Journal:  Pharm Res       Date:  1994-02       Impact factor: 4.200

Review 9.  Controlled release metoprolol formulations. A review of their pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and ischaemic heart disease.

Authors:  G L Plosker; S P Clissold
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546

10.  The effects of captopril vs atenolol on memory, information processing and mood: a double-blind crossover study.

Authors:  I J Deary; S Capewell; C Hajducka; A L Muir
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.